- [ 2024-08-05 ] 보건복지부 국장급 개방형 직위(감사관) 공개모집 안내
- [ 2024-07-31 ] 『생명윤리 언론동향 브리프』 제14호 발간 안내
- [ 2024-07-30 ] [제64회 콜로키움] 디지털 전환의 사회적 영향과 대응방안 : 메타...
- [ 2024-07-25 ] 2024년도 하반기 기관생명윤리위원회 평가·인증 계획 추가 공고
- [ 2024-07-25 ] [ISSCR 가이드라인 한국어 번역본] 발행 안내
| 발행년 : | 2008 |
|---|---|
| 구분 : | 국내학술지 |
| 학술지명 : | JKMA : 대한의사협회지 v.51 no.6 |
| 관련링크 : | http://kmbase.medric.or.kr/Main.aspx?men...0510060524 |
무의미한 연명치료를 거부할 권리
End-of-life Decision in Korea
/ 허대석 ( Heo Dae-Seok ) - 서울대학교 의과대학 내과학교실
대한의사협회지 2008년 51권 6호 p.524 ~ 529
Abstract
There are more than 65,000 cancer deaths per year in Korea. To what extent should we continue aggressive treatment in terminal patients? In the course of clinical care of a critically ill patient it may become clear that the patient is inevitably dying, the goal of medical treatment should not be to prolong the dying process without benefit to the patient or to others. Further intervention which will do no more than prolong the active dying process is often described as “futile.” Even though hospice is widely accepted in Korea, there is still controversy about withholding or withdrawing life-sustaining treatment. Conflicts between the parties may interrupt satisfactory decision-making and adversely affect patient care, family satisfaction, and physicianclinical team functioning. When further intervention to prolong the life of a patient becomes futile,
physicians have an obligation to shift the intent of care toward comfort and closure. However, there are necessary value judgments involved in coming to the assessment of futility. In this context, Korean society needs consensus agreement on futility issue, based on our own social values.
KeyWords
치료 무용, 생명연장 치료, 말기 환자
Futility, Life-sustaining treatment, Terminal patient
http://kmbase.medric.or.kr/Main.aspx?menu=01&d=KMBASE&m=VIEW&i=0614720080510060524
Copyright (c)KONIBP All Right Reserved.
2sisstore
